Latest Shareholders News

Carnaby Resources’ acquisition by Evolution Mining has become legally effective after court approval orders were lodged with ASIC. Trading suspension is expected from the close of 30 October, with implementation and ASX delisting scheduled for November.

Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.

ABx Group has completed its $2 million underwritten share purchase plan, with shareholders subscribing for $1.1 million and the remaining shortfall placed through the underwriter. The raising delivers fresh capital but also adds 95.2 million shares and 238.1 million options across the transaction.

Butn has extended its MYOB invoice finance agreement to November 2027, while assessing seven confidential, non-binding offers for the whole or parts of the group. The company is also negotiating changes to its Northleaf finance facility amid challenging operating conditions.

Aspire Mining has moved the Ovoot Coking Coal Project from planning into site establishment, while its new bond programme has raised US$11.2 million. The funding progress comes alongside only US$2.1 million in quarter-end cash and an estimated 1.8 quarters of available funding.

Identitii lifted annual recurring revenue 21% to $865,000 and expanded its sales pipeline 70% during the September quarter as new transaction-monitoring tools went live. But the fintech ended the period with negative cash of $44,000, leaving its near-term funding position dependent on further convertible-note proceeds and improved operating cash flow.

Focus Minerals generated A$180.1 million in customer receipts during the September quarter, while Bonnie Vale underground production rose alongside stable processing at Coolgardie. The company finished with A$184.6 million in cash, a A$95.1 million term deposit and a fully franked dividend paid to shareholders.

Zicom Group delivered a third consecutive profitable year, but revenue and shareholder earnings fell sharply after major gas-processing projects were completed. The ASX-listed industrial group has strengthened its balance sheet, though dividends remain deferred while it repays an $8.72 million shareholder loan.

Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.

Clime Investment Management delivered a 57% rise in FY26 net profit and lifted funds under management and advice by 9.4% in the September quarter. But additional valuation work on private credit and unlisted assets has delayed the audit process and payment of the performance fee.

Terrain Minerals has started its largest-ever Smokebush drilling campaign after establishing a 54,000-ounce inferred gold resource at Lightning, while newly identified tungsten adds a second critical-minerals angle. The exploration momentum comes with a clear funding constraint: quarter-end cash covered only 1.16 quarters of reported outgoings, before the company placed its remaining rights issue shortfall.

Cyprium Metals has secured an approximately A$20.7 million institutional placement and outlined a proposed debt extension that could take its staged Nifty funding package to A$83 million. The capital is aimed at advancing the open-pit feasibility study, infrastructure upgrades and a major SXEW expansion while first cathode production remains targeted for Q4 2026.